Merck has launched the Chemisphere app, a digital tool that enables scientists to easily access product documentation and ...
Merck’s search for its next blockbuster product continues to go beyond cancer. The pharmaceutical giant has agreed to pay $10.8 billion to acquire Prometheus Biosciences, a biotech with a Phase ...
Keytruda sales totaled $5,795 million in Q1 2023, up 17% year-on-year, thanks partly to an increase in its indications for use. At the same time, Robert Davis does not actively use the share buyback ...
Zacks Investment Research on MSN
Why Merck's 32% rally isn't enough to change the bearish view
Merck’s MRK stock has risen 32.3% in the past three months. The stock has also been trading above its 50-day and 200-day ...
WHITEHOUSE STATION, N.J. & SEOUL, South Korea — Merck, (NYSE: MRK) known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., entered into an agreement to develop and ...
Enhanced strategic and operational focus on key drivers to accelerate growth, Improved agility to anticipate and respond to customer needs and rapidly evolving market dynamics, Simplified operating ...
NEW YORK, Dec 11 (Reuters) - Merck & Co said on Tuesday it plans to begin late-stage trials next year on a drug to raise "good" HDL cholesterol that has not been dogged by the problems that sank a ...
Merck & Co. Inc. on Monday gained U.S. regulatory approval for a vaccine that could become a tough competitor to one of Pfizer Inc.’s top-selling products. The Food and Drug Administration on Monday ...
Merck stock surges 30% on strong fundamentals, regulatory catalysts, and attractive valuation. See why I rate the MRK stock a Strong Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback